LGG-26. Predicting MAPK inhibitor sensitivity in pediatric low-grade gliomas with novel gene expression-derived signatures

Pediatric low-grade glioma (pLGG), the most common brain tumors in children, are driven by alterations in the MAPK pathway. Several clinical trials have shown the potential for MAPK inhibitor (MAPKi) treatment in pLGG. However, the range of response to MAPKi is heterogeneous, even between tumors sha...

Descripción completa

Detalles Bibliográficos
Autores principales: Sigaud, Romain, Heß, Caroline, Hielscher, Thomas, Winkler, Nadine, Selt, Florian, Kocher, Daniela, Nonnenbroich, Leo, Usta, Diren, Sommerkamp, Alex, Büdenbender, Isabel, Capper, David, Thomale, Ulrich W, Driever, Pablo Hernáiz, le Simon, Michè, Koch, Arend, Jabado, Nada, Andrade, Augusto F, van Meeteren, Netteke Schouten-, Hoving, Eelco, van Tilburg, Cornelis M, Pfister, Stefan M, Witt, Olaf, Jones, David T W, Milde, Till
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Low Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165112/
http://dx.doi.org/10.1093/neuonc/noac079.340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165112/
http://dx.doi.org/10.1093/neuonc/noac079.340

Ejemplares similares